Top

Published in:

01-11-2011 | Brief Report

What can we learn from the age- and race/ethnicity- specific rates of inflammatory breast carcinoma?

Authors: Dora Il’yasova, Sharareh Siamakpour-Reihani, Igor Akushevich, Lucy Akushevich, Neil Spector, Joellen Schildkraut

Published in: Breast Cancer Research and Treatment | Issue 2/2011

Abstract

Inflammatory Breast Carcinoma (IBC), the most aggressive type of breast tumor with unique clinicopathological presentation, is hypothesized to have distinct etiology with a socioeconomic status (SES) component. Using the Surveillance, Epidemiology and End Results (SEER) Program data for 2004–2007, we compare incidence rates of IBC to non-inflammatory locally advanced breast cancer (LABC) among racial/ethnic groups with different SES. The analysis includes women 20–84 years of age. To examine evidence for the distinct etiology of IBC, we analyzed age-distribution patterns of IBC and non-inflammatory LABC, using a mathematical carcinogenesis model. Based on the Collaborative Staging Extension codes, 2,942 incident IBC cases (codes 71 and 73) and 5,721 non-inflammatory LABC cases (codes 40–62) were identified during the four-year study period. Age-adjusted rates of IBC among non-Hispanic White and Hispanic women were similar (2.5/100,000 in both groups). Similar rates were also found in non-inflammatory LABC in these two groups (4.8/100,000 and 4.2/100,000, respectively). In African-American women, the IBC (3.91/100,000) and non-inflammatory LABC (8.47/100,000) rates were greater compared with other ethnic/racial sub-groups. However, the ratio of rates of IBC/non-inflammatory LABC was similar among all the racial/ethnic groups, suggesting that African-American women are susceptible to aggressive breast tumors in general but not specifically to IBC. The mathematical model successfully predicted the observed age-specific rates of both examined breast tumors and revealed distinct patterns. IBC rates increased until age 65 and then slightly decreased, whereas non-inflammatory LABC rates steadily increased throughout the entire age interval. The number of critical transition carcinogenesis stages (m-stages) predicted by the model were 6.3 and 8.5 for IBC and non-inflammatory LABC, respectively, supporting different etiologies of these breast tumors.

Robertson FM, Bondy M, Yang W et al (2010) Inflammatory breast cancer: the disease, the biology, the treatment. CA Cancer J Clin 60(6):351–375PubMedCrossRef

Cristofanilli M, Buchholz TA (2010) Proceedings of the first international inflammatory breast cancer conference. Cancer 116(11 Suppl):2729PubMedCrossRef

Dawood S, Merajver SD, Viens P et al (2011) International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Ann Oncol 22(3):515–523PubMedCrossRef

Anderson WF, Chu KC, Chang S (2003) Inflammatory breast carcinoma and noninflammatory locally advanced breast carcinoma: distinct clinicopathologic entities? J Clin Oncol 21(12):2254–2259PubMedCrossRef

Boussen H, Bouzaiene H, Ben JH et al (2010) Inflammatory breast cancer in Tunisia: epidemiological and clinical trends. Cancer 116(11 Suppl):2730–2735PubMedCrossRef

Boussen H, Bouzaiene H, Ben JH, Gamoudi A, Benna F, Rahal K (2008) Inflammatory breast cancer in Tunisia: reassessment of incidence and clinicopathological features. Semin Oncol 35(1):17–24PubMedCrossRef

Labidi SI, Mrad K, Mezlini A et al (2008) Inflammatory breast cancer in Tunisia in the era of multimodality therapy. Ann Oncol 19(3):473–480PubMedCrossRef

Ionta MT, Atzori F, Massidda B (2010) Inflammatory breast cancer in Italy: epidemiological and clinical aspects. Cancer 116(11 Suppl):2736–2740PubMedCrossRef

Wingo PA, Jamison PM, Young JL, Gargiullo P (2004) Population-based statistics for women diagnosed with inflammatory breast cancer (United States). Cancer Causes Control 15(3):321–328PubMedCrossRef

10.

Hance KW, Anderson WF, Devesa SS, Young HA, Levine PH (2005) Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute. J Natl Cancer Inst 97(13):966–975PubMedCrossRef

11.

Levine PH, Veneroso C (2008) The epidemiology of inflammatory breast cancer. Semin Oncol 35(1):11–16PubMedCrossRef

12.

Dawood S, Ueno NT, Valero V et al (2011) Differences in survival among women with stage III inflammatory and noninflammatory locally advanced breast cancer appear early: a large population-based study. Cancer 117(9):1819–1826PubMedCrossRef

13.

Chang S, Parker SL, Pham T, Buzdar AU, Hursting SD (1998) Inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program of the National Cancer Institute, 1975–1992. Cancer 82(12):2366–2372PubMedCrossRef

14.

Anderson WF, Schairer C, Chen BE, Hance KW, Levine PH (2005) Epidemiology of inflammatory breast cancer (IBC). Breast Dis 22:9–23PubMed

15.

Baquet CR, Commiskey P (2000) Socioeconomic factors and breast carcinoma in multicultural women. Cancer 88(5 Suppl):1256–1264PubMedCrossRef

16.

Dunn BK, Agurs-Collins T, Browne D, Lubet R, Johnson KA (2010) Health disparities in breast cancer: biology meets socioeconomic status. Breast Cancer Res Treat 121(2):281–292PubMedCrossRef

17.

The US Census Bureau (2010) About poverty: highlights for the calendar year of 2009. The US Census Bureau, Washington, DC

18.

Surveillance, Epidemiology, and End Results (SEER) Program (2010). SEER*Stat database: SEER 17 registeries research data and Hurricane Katrina impacted Louisiana cases. www.seer.cancer.gov

19.

Taylor SH, Walters R (2010) Potential impact of tumor registry rule changes for recording inflammatory breast cancer. Cancer 116(11 Suppl):2745–2747PubMedCrossRef

20.

Hankey BF, Ries LA, Edwards BK (1999) The surveillance, epidemiology, and end results program: a national resource. Cancer Epidemiol Biomarkers Prev 8(12):1117–1121PubMed

21.

Collaborative Staging Task Force of the American Joint Committee on Cancer (2007) Collaborative staging manual and coding instructions, version 01.04.00. U.S. Department of Health and Human Services, Washington DC

22.

Manton KG, Akushevich I, Kravchenko J (2009) Cancer mortality and morbidity patterns in the U.S. population: an interdisciplinary approach. Springer, New YorkCrossRef

23.

Kravchenko J, Akushevich I, Seewaldt VL, Abernethy AP, Lyerly HK (2011) Breast cancer as heterogeneous disease: contributing factors and carcinogenesis mechanisms. Breast Cancer Res Treat 128(2):483–493

24.

Manton KG, Akushevich I, Kulminski A (2008) Human mortality at extreme ages: data from the NLTCS and linked Medicare records. Math Popul Stud 15(3):137–159CrossRef

25.

Clemons M, Goss P (2001) Estrogen and the risk of breast cancer. N Engl J Med 344(4):276–285PubMedCrossRef

Title: What can we learn from the age- and race/ethnicity- specific rates of inflammatory breast carcinoma?
Authors: Dora Il’yasova
Sharareh Siamakpour-Reihani
Igor Akushevich
Lucy Akushevich
Neil Spector
Joellen Schildkraut
Publication date: 01-11-2011
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 2/2011
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-011-1719-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2011

Age-specific trends of survival in metastatic breast cancer: 26 years longitudinal data from a population-based cancer registry in Stockholm, Sweden

A retrospective study of breast cancer subtypes: the risk of relapse and the relations with treatments

Association between polymorphisms of the renin–angiotensin system genes and breast cancer risk: a meta-analysis

Risk factors by molecular subtypes of breast cancer across a population-based study of women 56 years or younger

Struggling with subtypes: trying to bridge the gap between molecular breast cancer subtypes and clinical management

Resveratrol suppresses growth of cancer stem-like cells by inhibiting fatty acid synthase

Keynote webinar | Spotlight on antibody–drug conjugates in cancer